v3.26.3
Stockholders' equity
 6 Months Ended
Sep. 30, 2026
Stockholders’ equity [Abstract]  
Stockholders' equity
6. Stockholders’ equity
 
Preferred Stock
 
The Company is authorized to issue up to 10,000,000 shares of preferred stock, par value $0.0001 per share. No shares of the Company’s preferred stock are issued or outstanding as of September 30, 2026.
 
Common Stock
 
In connection with the consummation of the Domestication, on October 7, 2024, the Company adopted a Certificate of Incorporation (as amended, the “Charter”) and Bylaws (as amended, the “Bylaws”). The rights of holders of Common Stock are governed by the Charter, the Bylaws, and the General Corporation Law of the State of Delaware. The Company is authorized to issue up to 100,000,000 shares of Common Stock, par value $0.0001 per share.
 
2026 Private Placement
 
In August 2026, the Company entered into a securities purchase agreement (the “2026 Purchase Agreement”) with certain institutional and accredited investors in connection with a private placement of shares of Common Stock (the “2026 Private Placement”). Pursuant to the 2026 Purchase Agreement, the Company offered and sold in the 2026 Private Placement an aggregate of 4,761,904 shares of Common Stock at a purchase price of $2.10 per share. The net proceeds to the Company from the 2026 Private Placement were $9,203, after deducting fees and expenses.
The Company’s pre-funded warrants and common warrants issued in February 2025 are presented under additional paid-in capital in the equity section of the unaudited condensed consolidated balance sheet as of September 30, 2026.
 
During the three and six months ended September 30, 2026, 0 and 250,000 of the pre-funded warrants issued in February 2025 were exercised for 0 and 250,000 shares of Common Stock, respectively.
 
The Company’s pre-funded warrants issued in September 2023 are presented under additional paid-in capital in the equity section of the unaudited condensed consolidated balance sheet as of September 30, 2026. There have been no exercises of the pre-funded warrants issued in September 2023 during the three and six months ended September 30, 2026
 
The following table summarizes the Company’s outstanding warrants as of September 30, 2026, all of which are exercisable for shares of Common Stock:
 
                
September 30, 2026
    No. of
warrants 		    Exercise
Price ($) 		    Expiration
Date 		 
Equity classified warrants
              
Pre-funded warrants issued in connection with September 2023 private placement
  338,252    0.0001    
No expiration
 
Common warrants issued in connection with February 2025 private placement
  4,418,292    3.395    (1) 
Pre-funded warrants issued in connection with February 2025 private placement
  657,708    0.0001    
No expiration
 
 
1)
The February 2025 common warrants will expire on the earlier of: (i) the 60th day after the date the FDA approves the NDA for GTx-104 and (ii) September 25, 2028.